Aloia J F, Kapoor A, Vaswani A, Cohn S H
Metabolism. 1981 Nov;30(11):1076-9. doi: 10.1016/0026-0495(81)90050-0.
A two compartment, double-blind, randomized, parallel study was performed comparing methandrostenolone with placebo in the treatment of osteoporosis. The duration of the study was 24 mo. Dependent parameters included total body calcium (TBCa), measured by neutron activation analysis: bone mineral content of the radius (BMC), measured by photon absorptiometry; and total body potassium (TBK), measured by total body counting. A significant increase in TBK occurred in the treated group, primarily in the first 6 mo; thereafter the TBK remained fairly constant. No significant changes in bone mass occurred, except the 6 mo TBCa measurement increased by 11 grams for the methandrostenolone group and decreased by 6 grams for the placebo group (p = .05). Other evidence also suggests that anabolic steroids may not produce sustained uncoupling of bone formation and bone resorption in osteoporosis. If methandrostenolone is capable of producing an increment in bone mass in osteoporosis, it was not readily observable with the sensitivity of the techniques employed in this study
进行了一项双盲、随机、平行的两分组研究，比较美雄酮与安慰剂治疗骨质疏松症的效果。研究持续时间为24个月。相关参数包括通过中子活化分析测量的全身钙（TBCa）；通过光子吸收法测量的桡骨骨矿物质含量（BMC）；以及通过全身计数测量的全身钾（TBK）。治疗组的TBK显著增加，主要在前6个月；此后TBK保持相当稳定。除了美雄酮组6个月时TBCa测量值增加了11克，安慰剂组减少了6克（p = 0.05）外，骨量没有显著变化。其他证据也表明，合成代谢类固醇可能不会在骨质疏松症中产生持续的骨形成与骨吸收解偶联。如果美雄酮能够增加骨质疏松症患者的骨量，那么在本研究采用的技术灵敏度下，这种增加并不容易观察到
